Triple Negative Breast Cancer Treatment Market to Reach $1.04 Billion, with a CAGR of 4.6% By 2034
July 02, 2024 07:30 ET
|
FACT.MR
Rockville, MD, July 02, 2024 (GLOBE NEWSWIRE) -- According to a recently released research report by Fact.MR, the global triple-negative breast cancer treatment market size is estimated at US$ 670.5...
ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis
January 17, 2024 07:52 ET
|
ZyVersa Therapeutics
NLRP3 Inflammasome Activation Is Linked to Brain Metastasis in Patients with Triple-Negative Breast Cancer.
Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer
December 23, 2022 08:00 ET
|
Immutep Limited
Agreement with FDA on Phase II/III trial design positions the Company to exploit eftilagimod alpha’s potential to address high unmet need for metastatic breast cancer patientsPatient population...
Therabest and Glycotope to assess Therabest’s iPSC-derived NK cell product TB-100 in combination with Glycotope’s GT-00AxIL15 immuno-cytokine for development in triple negative breast cancer
December 13, 2022 02:00 ET
|
Glycotope
Therabest and Glycotope to assess Therabest’s iPSC-derived NK cell product TB-100 in combination with Glycotope’s GT-00AxIL15 immuno-cytokine for development in triple negative breast cancer San...
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
October 04, 2021 17:34 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that a first patient has been dosed...
Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
June 27, 2019 08:30 ET
|
Zenith Capital Corp.
CALGARY, Alberta, June 27, 2019 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a wholly-owned subsidiary of Zenith Capital Corp., announced today that it has dosed the...
Intensity Therapeutics Receives Fast Track Designation from U.S. FDA for Development of INT230-6 as Treatment for Relapsed or Metastatic Triple Negative Breast Cancer
April 17, 2019 07:35 ET
|
Intensity Therapeutics Inc
WESTPORT, Conn., April 17, 2019 (GLOBE NEWSWIRE) -- Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers...
Zenith Epigenetics Announces U.S. FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program
March 18, 2019 09:00 ET
|
Zenith Capital Corp.
Pfizer / Zenith TNBC program collaboration on target to dose first patient in April 2019 Phase 2 mCRPC program and clinical data to be presented at AACR CALGARY, Alberta, March 18, 2019 (GLOBE...
Insight Genetics Launches First-of-its-kind Test for Triple Negative Breast Cancer
December 03, 2018 09:36 ET
|
Insight Genetics
NASHVILLE, Tenn., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Insight Genetics, Inc. today announced the launch of its proprietary Insight TNBCtype™, a new test for categorizing triple negative breast cancer...
Zenith Epigenetics Announces Clinical Trial Collaboration with Pfizer
November 20, 2018 08:30 ET
|
Zenith Capital Corp.
Collaboration to evaluate ZEN-3694 in combination with Talazoparib in TNBC patients; Phase 1b/2 trial expected to initiate 1Q 2019 CALGARY, Alberta, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Zenith...